Bexorg announces multi-program research collaboration with Biohaven

Bexorg, which describes itself as “a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system disorders,” announced a multi-program research collaboration with Biohaven (BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. “As part of the collaboration, Bexorg’s novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven,” the company stated. “As part of the collaboration, Bexorg aims to deliver insights from systemic delivery of Biohaven’s therapeutics, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. Data generated from the platform may also potentially point to the responsiveness of patient subpopulations and identify novel biomarkers to inform clinical trials. Financial terms of the collaboration were not disclosed,” the company added.